Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 20/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10236168 | 1.00 | MAPK1 (1.00) | MAPK1RPS6KA3 | |
| SCHEMBL14452909 | 1.00 | MAPK1 (1.00) | MAPK1RPS6KA3 | |
| SCHEMBL10236105 | 0.93 | MAPK1 (0.87) | MAPK1RPS6KA3 | |
| SCHEMBL7874415 | 0.93 | MAPK1 (0.87) | MAPK1RPS6KA3 | |
| SCHEMBL10236146 | 0.93 | MAPK1 (0.87) | MAPK1RPS6KA3 | |
| SCHEMBL13118891 | 0.92 | MAPK1 (0.85) | MAPK1RPS6KA3 | |
| SCHEMBL10236174 | 0.92 | MAPK1 (0.85) | MAPK1RPS6KA3 | |
| SCHEMBL13118835 | 0.92 | MAPK1 (0.84) | MAPK1RPS6KA3 | |
| SCHEMBL13118861 | 0.91 | MAPK1 (0.84) | MAPK1RPS6KA3 | |
| SCHEMBL13119164 | 0.91 | MAPK1 (0.84) | MAPK1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268897-A1 | Phosphatase Binding Compounds and Methods of Using Same | YALE UNIVERSITY | 2020-08-27 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7807672-B2 | Compounds that are ERK inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807672-B2 | Compounds that are ERK inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268897-A1 | Phosphatase Binding Compounds and Methods of Using Same | PPP5C, PPP4C, DUSP26 | MAPK1 1118/4885RPS6KA3 675/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | MAPK1 1/4885RPS6KA3 129/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | MAPK1 277/4885RPS6KA3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.